CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Seamless Therapeutics
Company type: Clinical
Main focus: Programmable recombinases
Company stage: Pre-clinical
Diseases: Not disclosed
Genome-editing tool: Programmable designer recombinases
Funding stage: Seed Funding (12.5M)
Location: Dresden, Germany
Website: https://seamlesstx.com/#about_us
Pipeline: Not disclosed
Partners:
Seamless Therapeutics leverages forced evolution to generate target-specific recombinases to address several clinically-relevant conditions. Evolved recombinases hold the potential for safer, more precise, and more efficient genome editing without the need to induced target DNA double-stranded breaks.
